J Korean Cancer Assoc.  2000 Aug;32(4):690-698.

A Phase II Study with Vinorelbine and Carboplatin in Patients with Advanced Non-small Cell Lung Cancer

• Kim JL
• Kim BS
• Na BJ
• So MJ
• Lee JH
• Chung OY
• Lee GL
• Roh YH

Abstract

PURPOSE: To evaluate the efficacy and safety of vinorelbine and carboplatin in advanced non- small-cell lung cancer (NSCLC).
MATERIALS AND METHODS
Between August 1998 and July 1999, 25 patients were enrolled. The median age was 68 (range, 46~77) years and male:female ratio was 23:2. Two patients had stage IIIa, 15 had stage IIIb and 8 had stage IV. Sixteen patients had ECOG performance status of 0 or 1 and 9 had 2 or 3. Sixteen patients had squamous cell carcinoma, 8 had adenocarcinoma and 1 had undifferentiated NSCLC. Treatment consists of intravenous carboplatin 400 mg/m2 on day 1 and vinorelbine 25 mg/m2 on days 1 and 8. The treatment was repeated every 28 days.
RESULTS
Twenty-three of 25 patients were evaluable. Partial response were observed in 11 patients. The overall response rate was 48% (95% confidence interval: 27~69%) and the median response duration was 19 (range 7 ~44 ) weeks. The median survival of 25 patients was 52 (range 3~53 ) weeks. Toxicities were evaluated by WHO criteria. During a total of 108 cycles, granulocytopenia worse than WHO grade 3 occurred in 2%, thrombocytopenia in 4% and anemia in 10%, respectively. Treatment-related death occurred in 1 patient due to sepsis during cytopenic period. Non-hematologic toxicity was minor and easily controlled.
CONCLUSION
A combination chemotherapy of intravenous vinorelbine and carboplatin has relatively high activity with acceptable toxicities in patients with advanced NSCLC.

Keyword

Non-small cell lung cancer; Vinorelbine; Carboplatin; Chemotherapy

MeSH Terms

Adenocarcinoma
Agranulocytosis
Anemia
Carboplatin*
Carcinoma, Non-Small-Cell Lung*
Carcinoma, Squamous Cell
Drug Therapy
Drug Therapy, Combination
Humans
Lung Neoplasms
Sepsis
Thrombocytopenia
Carboplatin